We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.
Novel targets

We are Galapagos

Galapagos discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in clinical development in multiple diseases. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and available to patients in Europe, Great Britain and Japan (under a collaboration with Gilead) for rheumatoid arthritis.

Learn more about Galapagos



All Galapagos news



All Galapagos events

Job Openings


All Current Openings